Abstract P6-03-20: The development and characterization of novel HER2-positive breast cancer models of acquired neratinib resistance

Cancer Models ◽

Abstract 1077: Acquired neratinib resistance is associated with acquisition ofHER2andPIK3CAmutations and can be overcome using potent drug combinations in HER2-positive breast cancer models

10.1158/1538-7445.am2021-1077 ◽

2021 ◽

Author(s):

Jamunarani Veeraraghavan ◽

Ragini Mistry ◽

Sarmistha Nanda ◽

Sreyashree Bose ◽

Chia Chia Liu ◽

...

Keyword(s):

Breast Cancer ◽

Drug Combinations ◽

Her2 Positive ◽

Cancer Models ◽

Potent Drug ◽

Synthesis and Characterization of Lipid Immuno-Nanocapsules for Directed Drug Delivery: Selective Antitumor Activity against HER2 Positive Breast-Cancer Cells

Biomacromolecules ◽

10.1021/bm401103t ◽

2013 ◽

Vol 14 (12) ◽

pp. 4248-4259 ◽

Cited By ~ 8

Author(s):

Paola Sánchez-Moreno ◽

Juan Luis Ortega-Vinuesa ◽

Houría Boulaiz ◽

Juan Antonio Marchal ◽

José Manuel Peula-García

Keyword(s):

Breast Cancer ◽

Drug Delivery ◽

Antitumor Activity ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Synthesis And Characterization ◽

Her2 Positive ◽

Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models

10.1158/1538-7445.am2020-1911 ◽

2020 ◽

Author(s):

Jamunarani Veeraraghavan ◽

Ragini Mistry ◽

Sarmistha Nanda ◽

Vidyalakshmi Sethunath ◽

Martin Shea ◽

...

Keyword(s):

Breast Cancer ◽

Acquired Resistance ◽

Cross Resistance ◽

Her2 Positive ◽

Cancer Models ◽

Abstract P3-08-24: Mutational characterization of HER2-positive breast cancer

10.1158/1538-7445.sabcs18-p3-08-24 ◽

2019 ◽

Author(s):

A Velasco Sánchez ◽

A Gasol Cudos ◽

S Morales ◽

J Veas Rodriguez ◽

A Serrate López ◽

...

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Abstract P3-03-06: Characterization of HER2-positive breast cancer (BC) cells selected for tolerance to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity (ADCC)

10.1158/1538-7445.sabcs16-p3-03-06 ◽

2017 ◽

Author(s):

T Biswas ◽

R Fritzemeier ◽

A Mark ◽

T Meißner ◽

B Young ◽

...

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Dependent Cell ◽

The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models

Annals of Oncology ◽

10.1093/annonc/mdz238.062 ◽

2019 ◽

Vol 30 ◽

pp. v18

Author(s):

N. Conlon ◽

A. Browne ◽

L. Breen ◽

M. Lowry ◽

L. O’Driscoll ◽

...

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Cancer Models ◽

Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models

BMC Medicine ◽

10.1186/1741-7015-10-80 ◽

2012 ◽

Vol 10 (1) ◽

Cited By ~ 51

Author(s):

Parul Gupta ◽

Sanjay K Srivastava

Keyword(s):

Breast Cancer ◽

Antitumor Activity ◽

Phenethyl Isothiocyanate ◽

Her2 Positive ◽

Cancer Models ◽

Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models

10.1158/1538-7445.am2016-2130a ◽

2016 ◽

Cited By ~ 1

Author(s):

Sonia Palomeras ◽

Angel Diaz-Lagares ◽

Sarrats Ariadna ◽

Crujeiras Ana Belen ◽

Giro-Perafita Ariadna ◽

...

Keyword(s):

Breast Cancer ◽

Epigenetic Silencing ◽

Trastuzumab Resistance ◽

Her2 Positive ◽

Cancer Models ◽

Abstract P6-10-25: Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer

10.1158/1538-7445.sabcs19-p6-10-25 ◽

2020 ◽

Author(s):

Kathleen M. Fenn ◽

Douglas K Marks ◽

Rami Vanguri ◽

Shuobo Boboila ◽

Hua Guo ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Immune Microenvironment ◽

Her2 Positive ◽

Tumor Immune Microenvironment ◽

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3239-5 ◽

2014 ◽

Vol 149 (2) ◽

pp. 373-383 ◽

Cited By ~ 23

Author(s):

N. Elster ◽

M. Cremona ◽

C. Morgan ◽

S. Toomey ◽

A. Carr ◽

...

Keyword(s):

Breast Cancer ◽

Targeted Therapies ◽

Acquired Resistance ◽

Her2 Positive ◽

Preclinical Evaluation ◽

Cancer Models ◽